Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04610788 · ClinicalTrials.gov registry record
Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 43
- Enrollment target
NCT04610788: Completed study, sponsored by Johns Hopkins University.
NCT04610788 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04610788 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure). The study will also help the investigators understand why people with PAH from an unknown cause (called idiopathic PAH, or IPAH) can also develop a weakened heart muscle. The response of the right side of the heart or right ventricle (RV) to standard PAH therapy in scleroderma-associated PAH and in IPAH will be assessed. Blood and tissue samples will be collected from research participants during participants' normal standard of care procedures. People with scleroderma-associated PAH or idiopathic cause (IPAH) who need a right heart catheterization may join this study.
Primary Outcome
Assessed on the clinical RHC as normal, moderately reduced, or severely reduced.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-04-15 |
| Est. Completion | 2025-12-31 |
What the finished NCT04610788 record still lists
NCT04610788 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04610788 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04610788 about?
NCT04610788 is a clinical study titled "Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH". This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure). The study will also help the investigators understand why people with PAH from an ...
What is the current status of trial NCT04610788?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2019-04-15. Estimated completion is 2025-12-31.
Who is sponsoring clinical trial NCT04610788?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI